I Nájera

Author PubWeight™ 7.00^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility.	J Virol	1996	2.03
2	Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group.	J Infect Dis	2000	1.37
3	Point mutant frequencies in the pol gene of human immunodeficiency virus type 1 are two- to threefold lower than those of env.	AIDS Res Hum Retroviruses	1996	1.03
4	Tumor size as predictor of microinvasion, invasion, and axillary metastasis in ductal carcinoma in situ.	J Exp Clin Cancer Res	2006	0.92
5	Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir.	Antimicrob Agents Chemother	2012	0.85
6	Intracellular effects of the Hepatitis C virus nucleoside polymerase inhibitor RO5855 (Mericitabine Parent) and Ribavirin in combination.	Antimicrob Agents Chemother	2014	0.75
7	Molecular epidemiology of HIV-1 in Madrid.	Virus Res	1994	0.75